Table 1 |
|||||||
|
Results of the technical comparison of indirect immunofluorescence (IIF), immunoblot and ELISA for the detection of anti-polymyositis/scleroderma (anti-PM/Scl) antibodies |
|||||||
|
Sample number |
IIF |
Immunoblot |
ELISA |
||||
|
|
|||||||
|
Titer |
Pattern |
PM/Scl-75 |
PM/Scl-100 |
Other |
PM/Scl-100 |
PM1-α |
|
|
|
|||||||
|
1 |
1:10000 |
FG, N |
++ |
+++ |
15.3 |
17.7 |
|
|
2 |
1:1000 |
FG, N |
+ |
+ |
2.9 |
7.6 |
|
|
3 |
1:3200 |
FG, N |
++ |
++ |
14.4 |
29.2 |
|
|
1:320 |
AMA |
||||||
|
4 |
1:320 |
FG, N |
- |
+ |
1.1 |
4.7 |
|
|
5 |
1:1000 |
FG, N |
+ |
+ |
2.2 |
12.1 |
|
|
6 |
1:3200 |
FG, N |
- |
- |
0.6 |
2.3 |
|
|
7 |
1:1000 |
FG, N |
++ |
+++ |
5.2 |
13.3 |
|
|
8 |
1:1000 |
FG, N |
+ |
+ |
2.3 |
12.7 |
|
|
9 |
1:3200 |
FG, N |
+ |
+++ |
P38 |
15.5 |
36.1 |
|
10 |
- |
- |
+ |
1.7 |
4.0 |
||
|
11 |
1:1000 |
FG, N |
- |
++ |
19.2 |
2.4 |
|
|
12 |
1:1000 |
FG, N |
++ |
+ |
1.2 |
3.2 |
|
|
13 |
1:3200 |
FG, N |
+++ |
+++ |
Ku86, Jo-1 |
6.5 |
10.6 |
|
14 |
1:3200 |
FG, N |
- |
++ |
2.1 |
5.9 |
|
|
15 |
1:3200 |
FG, N |
++ |
+++ |
11.4 |
22.5 |
|
|
16 |
1:1000 |
FG, N |
- |
+ |
3.6 |
8.5 |
|
|
17 |
1:1000 |
FG, N |
+ |
++ |
3.2 |
15.0 |
|
|
18 |
1:3200 |
FG, N |
++ |
++ |
6.1 |
11.8 |
|
|
19 |
n.d. |
n.d. |
- |
++ |
7.1 |
19.4 |
|
|
20 |
1:320 |
N |
- |
+ |
2.1 |
5.6 |
|
|
21 |
n.d. |
n.d. |
+++ |
++ |
4.1 |
12.8 |
|
|
22 |
1:10000 |
FG |
- |
+ |
P38 |
0.7 |
1.5 |
|
1:10000 |
SPA |
||||||
|
23 |
1:1000 |
N |
n.d. |
n.d. |
0.5 |
2.7 |
|
|
24 |
n.d. |
n.d. |
++ |
+++ |
18.2 |
34.7 |
|
|
25 |
1:10000 |
N |
n.d. |
n.d. |
P38 |
0.5 |
2.0 |
|
1:1000 |
Rib |
||||||
|
26 |
1:1000 |
N |
n.d. |
n.d. |
1.9 |
8.4 |
|
|
27 |
n.d. |
n.d. |
+ |
++ |
5.9 |
19.4 |
|
|
28 |
n.d. |
n.d. |
++ |
+++ |
20.9 |
37.3 |
|
|
29 |
1:1000 |
Hom |
n.d. |
n.d. |
Ku86, Cen, M2 |
0.6 |
0.8 |
|
1:100 |
N* |
||||||
|
30 |
1:1000 |
N |
- |
+ |
0.6 |
1.4 |
|
|
31 |
1:3200 |
Hom, N |
- |
- |
0.5 |
2.9 |
|
|
32 |
1:3200 |
N |
- |
- |
0.5 |
1.3 |
|
|
33 |
1:320 |
FG, N |
+ |
++ |
7.2 |
25.7 |
|
|
Number positive/tested |
26/29 |
17/29 |
27/29 |
26/33 |
32/33 |
||
|
|
|||||||
|
-, negative; +, weak positive; ++, positive; +++, strong positive; n.d., not determined; FG, fine granular; Hom, homogenous; SPA, spindle apparatus; N, nucleoli; AMA, anti-mitochondrial antibodies; Cen, centromere; Rib, ribosomal. * Primate liver. |
|||||||
|
Mahler et al. Arthritis Research & Therapy 2005 7:R704 doi:10.1186/ar1729 |
|||||||
